{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:21:18Z","timestamp":1787314878677,"version":"build-2736575974"},"reference-count":58,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":1492,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1124\/dmd.120.000207","type":"journal-article","created":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T23:50:13Z","timestamp":1602633013000},"page":"1257-1263","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Pharmacokinetic and Pharmacodynamic Factors Contribute to Synergism between Let-7c-5p and 5-Fluorouracil in Inhibiting Hepatocellular Carcinoma Cell Viability"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4215-9434","authenticated-orcid":false,"given":"Joseph L.","family":"Jilek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Juan","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1441-4012","authenticated-orcid":false,"given":"Ai-Ming","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.120.000207_bib1","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jamaoncol.2019.2792","article-title":"Assessment of treatment with sorafenib plus doxorubicin vs sorafenib alone in patients with advanced hepatocellular carcinoma: phase 3 CALGB 80802 randomized clinical trial","volume":"5","author":"Abou-Alfa","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1124\/dmd.120.000207_bib2","doi-asserted-by":"crossref","first-page":"e05005","DOI":"10.7554\/eLife.05005","article-title":"Predicting effective microRNA target sites in mammalian mRNAs","volume":"4","author":"Agarwal","year":"2015","journal-title":"eLife"},{"key":"10.1124\/dmd.120.000207_bib3","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/ncb2443","article-title":"Senescence is an endogenous trigger for microRNA-directed transcriptional gene silencing in human cells","volume":"14","author":"Benhamed","year":"2012","journal-title":"Nat Cell Biol"},{"key":"10.1124\/dmd.120.000207_bib4","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/hep.24682","article-title":"Adenosine triphosphate-binding cassette transporter genes up-regulation in untreated hepatocellular carcinoma is mediated by cellular microRNAs","volume":"55","author":"Borel","year":"2012","journal-title":"Hepatology"},{"key":"10.1124\/dmd.120.000207_bib5","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"10.1124\/dmd.120.000207_bib6","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/cmi.2013.51","article-title":"MicroRNA-let-7a promotes E2F-mediated cell proliferation and NF\u03baB activation in vitro","volume":"11","author":"Chafin","year":"2014","journal-title":"Cell Mol Immunol"},{"key":"10.1124\/dmd.120.000207_bib7","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41575-019-0240-9","article-title":"Harnessing big \u2018omics\u2019 data and AI for drug discovery in hepatocellular carcinoma","volume":"17","author":"Chen","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1124\/dmd.120.000207_bib8","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2174\/138161282005140214165212","article-title":"ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development","volume":"20","author":"Choi","year":"2014","journal-title":"Curr Pharm Des"},{"key":"10.1124\/dmd.120.000207_bib9","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol Rev"},{"key":"10.1124\/dmd.120.000207_bib10","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res"},{"key":"10.1124\/dmd.120.000207_bib11","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1128\/MCB.15.8.4215","article-title":"Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1\/S-regulatory genes","volume":"15","author":"DeGregori","year":"1995","journal-title":"Mol Cell Biol"},{"key":"10.1124\/dmd.120.000207_bib12","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/(SICI)1097-4644(20000401)77:1<50::AID-JCB6>3.0.CO;2-C","article-title":"Transcriptional control elements and complex initiation pattern of the TATA-less bidirectional human thymidylate synthase promoter","volume":"77","author":"Dong","year":"2000","journal-title":"J Cell Biochem"},{"key":"10.1124\/dmd.120.000207_bib13","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/00001813-199308000-00002","article-title":"Immunological quantitation of thymidylate synthase-FdUMP-5,10-methylenetetrahydrofolate ternary complex with the monoclonal antibody TS 106","volume":"4","author":"Drake","year":"1993","journal-title":"Anticancer Drugs"},{"key":"10.1124\/dmd.120.000207_bib14","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"10.1124\/dmd.120.000207_bib15","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1002\/cncr.32339","article-title":"Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma","volume":"125","author":"Feun","year":"2019","journal-title":"Cancer"},{"key":"10.1124\/dmd.120.000207_bib16","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.120.000207_bib17","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/1078-0432.CCR-18-0847","article-title":"A phase II and biomarker study of sorafenib combined with modified FOLFOX in patients with advanced hepatocellular carcinoma","volume":"25","author":"Goyal","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1124\/dmd.120.000207_bib18","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.2165\/11530870-000000000-00000","article-title":"New pharmacological developments in the treatment of hepatocellular cancer","volume":"69","author":"Gusani","year":"2009","journal-title":"Drugs"},{"key":"10.1124\/dmd.120.000207_bib19","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1124\/jpet.118.247775","article-title":"Bioengineered noncoding RNAs selectively change cellular miRNome profiles for cancer therapy","volume":"365","author":"Ho","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.120.000207_bib20","doi-asserted-by":"crossref","first-page":"30742","DOI":"10.18632\/oncotarget.16372","article-title":"Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models","volume":"8","author":"Jian","year":"2017","journal-title":"Oncotarget"},{"key":"10.1124\/dmd.120.000207_bib21","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.omtn.2019.01.007","article-title":"Bioengineered let-7c inhibits orthotopic hepatocellular carcinoma and improves overall survival with minimal immunogenicity","volume":"14","author":"Jilek","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1124\/dmd.120.000207_bib22","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.cell.2005.01.014","article-title":"RAS is regulated by the let-7 microRNA family","volume":"120","author":"Johnson","year":"2005","journal-title":"Cell"},{"key":"10.1124\/dmd.120.000207_bib23","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/sj.onc.1201520","article-title":"Regulation of c-myc expression by Ras\/Raf signalling","volume":"16","author":"Kerkhoff","year":"1998","journal-title":"Oncogene"},{"key":"10.1124\/dmd.120.000207_bib24","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1101\/gad.1812509","article-title":"HuR recruits let-7\/RISC to repress c-Myc expression","volume":"23","author":"Kim","year":"2009","journal-title":"Genes Dev"},{"key":"10.1124\/dmd.120.000207_bib25","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1124\/dmd.115.064493","article-title":"Chimeric microRNA-1291 biosynthesized efficiently in escherichia coli is effective to reduce target gene expression in human carcinoma cells and improve chemosensitivity","volume":"43","author":"Li","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000207_bib26","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1124\/dmd.117.078741","article-title":"Bioengineered NRF2-siRNA is effective to interfere with NRF2 pathways and improve chemosensitivity of human cancer cells","volume":"46","author":"Li","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000207_bib27","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.drup.2016.05.001","article-title":"Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms and novel therapeutic drug strategies","volume":"27","author":"Li","year":"2016","journal-title":"Drug Resist Updat"},{"key":"10.1124\/dmd.120.000207_bib28","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.120.000207_bib29","first-page":"2644","article-title":"The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolates","volume":"62","author":"Longley","year":"2002","journal-title":"Cancer Res"},{"key":"10.1124\/dmd.120.000207_bib30","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.1124\/dmd.120.000207_bib31","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1677\/erc.0.0080219","article-title":"Discovery of a novel Raf kinase inhibitor","volume":"8","author":"Lyons","year":"2001","journal-title":"Endocr Relat Cancer"},{"key":"10.1124\/dmd.120.000207_bib32","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.4161\/cc.6390","article-title":"Direct role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells","volume":"7","author":"Mannava","year":"2008","journal-title":"Cell Cycle"},{"key":"10.1124\/dmd.120.000207_bib33","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1124\/dmd.110.033613","article-title":"Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil","volume":"39","author":"Nambaru","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000207_bib34","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1158\/1535-7163.MCT-06-0529","article-title":"MRP8\/ABCC11 directly confers resistance to 5-fluorouracil","volume":"6","author":"Oguri","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/dmd.120.000207_bib35","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1124\/dmd.109.027680","article-title":"MicroRNAs regulate CYP3A4 expression via direct and indirect targeting","volume":"37","author":"Pan","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000207_bib36","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.bbrc.2007.09.037","article-title":"Bcl-xL blocks high dose doxorubicin-induced apoptosis but not low dose doxorubicin-induced cell death through mitotic catastrophe","volume":"363","author":"Park","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/dmd.120.000207_bib37","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0925-4439(02)00082-0","article-title":"Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism","volume":"1587","author":"Peters","year":"2002","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/dmd.120.000207_bib38","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.chembiol.2010.04.012","article-title":"DNA topoisomerases and their poisoning by anticancer and antibacterial drugs","volume":"17","author":"Pommier","year":"2010","journal-title":"Chem Biol"},{"key":"10.1124\/dmd.120.000207_bib39","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1158\/1535-7163.MCT-04-0291","article-title":"The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites","volume":"4","author":"Pratt","year":"2005","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/dmd.120.000207_bib40","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1093\/bioinformatics\/btx806","article-title":"DeepSynergy: predicting anti-cancer drug synergy with Deep Learning","volume":"34","author":"Preuer","year":"2018","journal-title":"Bioinformatics"},{"key":"10.1124\/dmd.120.000207_bib41","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1200\/JCO.2012.44.5643","article-title":"Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil\/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia","volume":"31","author":"Qin","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1124\/dmd.120.000207_bib42","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/14737140.2017.1338955","article-title":"Regorafenib for the treatment of unresectable hepatocellular carcinoma","volume":"17","author":"Rimassa","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1124\/dmd.120.000207_bib43","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1101\/gad.836800","article-title":"Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability","volume":"14","author":"Sears","year":"2000","journal-title":"Genes Dev"},{"key":"10.1124\/dmd.120.000207_bib44","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.stem.2013.03.005","article-title":"Lin28: primal regulator of growth and metabolism in stem cells","volume":"12","author":"Shyh-Chang","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1124\/dmd.120.000207_bib45","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1124\/dmd.120.000207_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.106.104117","article-title":"An overview of drug combination analysis with isobolograms","volume":"319","author":"Tallarida","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.120.000207_bib47","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1007\/s10495-008-0256-z","article-title":"Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3","volume":"13","author":"Tsang","year":"2008","journal-title":"Apoptosis"},{"key":"10.1124\/dmd.120.000207_bib48","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.canlet.2018.10.038","article-title":"Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models","volume":"442","author":"Tu","year":"2019","journal-title":"Cancer Lett"},{"key":"10.1124\/dmd.120.000207_bib49","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrd.2016.3","article-title":"Combination therapies in oncology","volume":"15","author":"Webster","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/dmd.120.000207_bib50","doi-asserted-by":"crossref","first-page":"17664","DOI":"10.1074\/jbc.M212723200","article-title":"Characterization of the MRP4- and MRP5-mediated transport of cyclic nucleotides from intact cells","volume":"278","author":"Wielinga","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.120.000207_bib51","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"10.1124\/dmd.120.000207_bib52","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.apsb.2019.11.001","article-title":"Bioengineered miR-328-3p modulates GLUT1-mediated glucose uptake and metabolism to exert synergistic antiproliferative effects with chemotherapeutics","volume":"10","author":"Yi","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1124\/dmd.120.000207_bib53","doi-asserted-by":"crossref","first-page":"6288","DOI":"10.1158\/0008-5472.CAN-06-0826","article-title":"Ras stimulation of E2F activity and a consequent E2F regulation of integrin alpha6beta4 promote the invasion of breast carcinoma cells","volume":"66","author":"Yoon","year":"2006","journal-title":"Cancer Res"},{"key":"10.1124\/dmd.120.000207_bib54","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.apsb.2012.02.011","article-title":"Noncoding microRNAs: small RNAs play a big role in regulation of ADME?","volume":"2","author":"Yu","year":"2012","journal-title":"Acta Pharm Sin B"},{"key":"10.1124\/dmd.120.000207_bib55","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1124\/dmd.115.067470","article-title":"MicroRNA pharmacoepigenetics: posttranscriptional regulation mechanisms behind variable drug disposition and strategy to develop more effective therapy","volume":"44","author":"Yu","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000207_bib56","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00280-008-0838-z","article-title":"Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer","volume":"63","author":"Yuan","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.120.000207_bib57","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.bcp.2015.10.015","article-title":"Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth","volume":"98","author":"Zhao","year":"2015","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.120.000207_bib58","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jamaoncol.2016.4115","article-title":"Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: analysis of REACH trial results by child-pugh score","volume":"3","author":"Zhu","year":"2017","journal-title":"JAMA Oncol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624078279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624078279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.120.000207","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T13:04:12Z","timestamp":1740747852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624078279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":58,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0090955624078279"],"URL":"https:\/\/doi.org\/10.1124\/dmd.120.000207","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic and Pharmacodynamic Factors Contribute to Synergism between Let-7c-5p and 5-Fluorouracil in Inhibiting Hepatocellular Carcinoma Cell Viability","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.120.000207","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by The Author(s)","name":"copyright","label":"Copyright"}]}}